Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Paola Villa, Valentina Elisabetta Bounous, Inbal Dona Amar, Federica Bernardini, Margherita Giorgi, Daniela Attianese, Annamaria Ferrero, Marika D'Oria, Giovanni Scambia
BACKGROUND: Advances in the treatment of gynecological cancer have led to improvements in survival but also an increase in menopausal symptoms, especially in young women with premature iatrogenic menopause. METHODS: A narrative review was performed to clarify the possibility of prescribing hormone replacement therapy (HRT) after hormone-dependent gynecological cancers (ovarian cancer [OC], cervical adenocarcinoma [AC], and endometrial cancer [EC]). RESULTS: HRT can be prescribed to patients with early-stage, grade I-II OC who experience bothersome menopausal symptoms non-responsive to alternative non-hormone therapy after optimal surgery...
March 1, 2024: Journal of Clinical Medicine
#22
REVIEW
Micaela Petrone, Martina Catania, Liliana Italia De Rosa, Rebecca S Degliuomini, Kristiana Kola, Chiara Lupi, Matteo Brambilla Pisoni, Stefano Salvatore, Massimo Candiani, Giuseppe Vezzoli, Maria Teresa Sciarrone Alibrandi
This review navigates the intricate relationship between gender, hormonal influences, and the progression of autosomal dominant polycystic kidney disease (ADPKD), highlighting the limited literature on this crucial topic. The study explores the impact of female sex hormones on liver and renal manifestations, uncovering gender-specific differences in disease progression. Actually, hormonal therapy in women with ADPKD remains a challenging issue and is a source of concern regarding its potential impact on disease outcomes, particularly at the hepatic level...
February 22, 2024: Journal of Clinical Medicine
#23
REVIEW
Mozhgan Vahabi Dastjerdi, Samaneh Sheibani, Maryam Taheri, Fouzieh Karami Hezarcheshmeh, Jamileh Jahangirian, Maryam Jazayeri, Hossein Hosseinirad, Tahereh Doohandeh, Rohollah Valizadeh
CONTEXT: The effect of platelet-rich plasma (PRP) on ovarian reserve markers in poor ovarian response (POR) is challenging. AIM: This systematic review and meta-analysis was, therefore, designed to evaluate the effectiveness of intra-ovarian injection of autologous PRP on improving ovarian reserve markers and assisted reproductive technology (ART) outcomes in infertile women with POR. METHODS: A systematic search was conducted for the efficacy of intra-ovarian injection of autologous PRP on the improvement of ovarian reserve markers and ART outcomes in infertile women with POR...
April 8, 2024: Archives of Gynecology and Obstetrics
#24
REVIEW
Graziamaria Corbi, Marika Comegna, Caterina Vinciguerra, Alessio Capasso, Luigi Onorato, Alfonso Maria Salucci, Antonio Rapacciuolo, Alessandro Cannavo
Sex differences are consistently identified in determining the prevalence, manifestation, and response to therapies in several systemic disorders, including those affecting the cardiovascular (CV), skeletal muscle, and nervous system. Interestingly, such differences are often more noticeable as we age. For example, premenopausal women experience a lower risk of CV disease than men of the same age. While at an advanced age, with menopause, the risk of cardiovascular diseases and adverse outcomes increases exponentially in women, exceeding that of men...
April 8, 2024: Experimental Gerontology
#25
JOURNAL ARTICLE
Jin-Sung Yuk
No abstract text is available yet for this article.
April 8, 2024: Obstetrics & Gynecology Science
#26
REVIEW
Mohsen M A Abdelhafez, Karim A M Ahmed, Nashwa A M Ahmed, Mohd H Ismail, Mohd N M Daud, Aya M E Eldiasty, Mohd F B Amri, Mohammad S Jeffree, Fairrul K Masnah, Dg M P Baharuddin, Mohd F Bolong, Mohd F Hayati, Nornazirah B Azizan, Doreen Sumpat, Syed S S Abdul Rahim, Win W Than, Mohd Y Ibrahim, Zhen Z Lo, May Z Soe
Menopausal hormone therapy (MHT) is known to increase the risk of venous thromboembolism (VTE), which includes deep vein thrombosis, pulmonary embolism, and less frequently cerebral vein thrombosis, but the absolute risk for a given patient is very low. After starting MHT, the risk of VTE seems to be at its highest, declining to the non-HRT user baseline level of risk after stopping. Whether estrogen-only or estrogen-progestin HRT combination is linked to a similar risk of VTE is unclear from the available evidence...
March 31, 2024: African Journal of Reproductive Health
#27
JOURNAL ARTICLE
Amal M Elhusein, Hammad A Fadlalmola, Huda H Abedelwahed, Alawìa A Elshaikh, Amel E Banaga, Manal H F Alrahman, Nafesa H Abdelgadim, Insaf H Mohammed, Afaf A A Abdalla, Fatma A M Abdalla, Ebtihag M Abd Allah, Nagwa I Abbas, Abdullah D Alhujaili, Egbal A Almkiy, Eltayeb A Idress, Eltayeb M Awadalkareem, Selwa Y Abdeldafie, Prema Balusamy, Rasha A Mohamed, Rami S M Aloufi, Mohammed Habiballa, Mohammed A Abdelmalik, Mohammed M Alhejaili, Ibrahim A Ibrahim, Huda K Masaad
Menopause represents the physiological transition when a woman's reproductive period ends associated with a variety of symptoms, including vasomotor symptoms, such as night sweats and hot flashes. This systematic review and meta-analysis aimed to assess the effectiveness and safety of oral Fezolinetant for treating vasomotor symptoms associated with menopause. Five electronic databases were searched from their inception until May 2023. Via the Cochrane risk of bias tool, two reviewers assessed the studies' quality...
March 31, 2024: African Journal of Reproductive Health
#28
REVIEW
Angela H E M Maas
There is an increasing interest among professionals in cardiovascular medicine in women-specific risk variables related to gynecologic conditions over the life span. Although adverse lifestyle factors, hypertension, dyslipidemia and insulin resistance are recognized as the most important risk factors in older women, there is still uncertainty over how to account for other risk variables. For instance, migraine from puberty onwards, chronic inflammatory conditions and mental stress affect cardiovascular risk in women...
March 21, 2024: Maturitas
#29
JOURNAL ARTICLE
Madeline Wood Alexander, Che-Yuan Wu, Gillian T Coughlan, Tanvi Puri, Rachel F Buckley, Priya Palta, Walter Swardfager, Mario Masellis, Liisa A M Galea, Gillian Einstein, Sandra E Black, Jennifer S Rabin
BACKGROUND AND OBJECTIVES: Mounting evidence supports sex differences in Alzheimer disease (AD) risk. Vascular and hormonal factors may together contribute to AD risk in female adults. We investigated whether age at menopause, vascular risk, and history of hormone therapy (HT) containing estrogens together influence cognition over a 3-year follow-up period. We hypothesized that earlier menopause and elevated vascular risk would have a synergistic association with lower cognitive scores at follow-up and that HT containing estrogens would attenuate this synergistic association to preserve cognition...
May 2024: Neurology
#30
JOURNAL ARTICLE
Amy Y Lee, Anna T Lyons, Vaia Makris, Sailaja Kamaraju, Melinda R Stolley, Joan M Neuner, Kathryn E Flynn
PURPOSE: Oral adjuvant endocrine therapy (AET) is an effective treatment for hormone receptor positive breast cancer to decrease recurrence and mortality, but adherence is poor. This study explored post-menopausal women's experiences with AET, with a particular focus on adherence to AET as well as distress and symptoms experienced prior to and during AET treatment. METHODS: Participants were recruited from a hospital registry, stratified by adherence to/discontinuation of AET...
April 2, 2024: Supportive Care in Cancer
#31
REVIEW
Panagiotis Anagnostis, Konstantinos Lallas, Anna Pappa, Georgios Avgeris, Kristina Beta, Dimitrios Damakis, Eirini Fountoukidou, Maria Zidrou, Irene Lambrinoudaki, Dimitrios G Goulis
BACKGROUND/AIMS: Vasomotor symptoms (VMS) adversely affect postmenopausal quality of life. However, their association with bone health has not been elucidated. This study aimed to systematically review and meta-analyze the evidence regarding the association of VMS with fracture risk and bone mineral density (BMD) in peri- and postmenopausal women. METHODS: A literature search was conducted in PubMed, Scopus and Cochrane databases until 31 August 2023. Fracture, low BMD (osteoporosis/osteopenia) and mean change in lumbar spine (LS) and femoral neck (FN) BMD were assessed...
April 2, 2024: Osteoporosis International
#32
JOURNAL ARTICLE
Danny Salazar-Pousada, Valeria Ortega-Uscocovich, Cecibel Ramírez-Morán, Peter Chedraui
OBJECTIVE: To assess menopausal symptoms and determine awareness of menopausal related information in mid-aged women. METHODS: This was a cross-sectional study in which 140 women aged 40 to 60 years from Guayaquil, Ecuador were surveyed with the short 10-item Cervantes Scale (CS-10) and a questionnaire containing personal data and questions assessing awareness of menopause related information. RESULTS: The mean age of the sample was 48...
December 2024: Gynecological Endocrinology
#33
JOURNAL ARTICLE
Yu Tian, Yi Lin, Conghui Qu, Volker Arndt, James W Baurley, Sonja I Berndt, Stephanie A Bien, D Timothy Bishop, Hermann Brenner, Daniel D Buchanan, Arif Budiarto, Peter T Campbell, Robert Carreras-Torres, Graham Casey, Andrew T Chan, Rui Chen, Xuechen Chen, David V Conti, Virginia Díez-Obrero, Niki Dimou, David A Drew, Jane C Figueiredo, Steven Gallinger, Graham G Giles, Stephen B Gruber, Marc J Gunter, Sophia Harlid, Tabitha A Harrison, Akihisa Hidaka, Michael Hoffmeister, Jeroen R Huyghe, Mark A Jenkins, Kristina M Jordahl, Amit D Joshi, Temitope O Keku, Eric Kawaguchi, Andre E Kim, Anshul Kundaje, Susanna C Larsson, Loic Le Marchand, Juan Pablo Lewinger, Li Li, Victor Moreno, John Morrison, Neil Murphy, Hongmei Nan, Rami Nassir, Polly A Newcomb, Mireia Obón-Santacana, Shuji Ogino, Jennifer Ose, Bens Pardamean, Andrew J Pellatt, Anita R Peoples, Elizabeth A Platz, John D Potter, Ross L Prentice, Gad Rennert, Edward A Ruiz-Narvaez, Lori C Sakoda, Robert E Schoen, Anna Shcherbina, Mariana C Stern, Yu-Ru Su, Stephen N Thibodeau, Duncan C Thomas, Konstantinos K Tsilidis, Franzel J B van Duijnhoven, Bethany Van Guelpen, Kala Visvanathan, Emily White, Alicja Wolk, Michael O Woods, Anna H Wu, Ulrike Peters, W James Gauderman, Li Hsu, Jenny Chang-Claude
BACKGROUND: Menopausal hormone therapy (MHT), a common treatment to relieve symptoms of menopause, is associated with a lower risk of colorectal cancer (CRC). To inform CRC risk prediction and MHT risk-benefit assessment, we aimed to evaluate the joint association of a polygenic risk score (PRS) for CRC and MHT on CRC risk. METHODS: We used data from 28,486 postmenopausal women (11,519 cases and 16,967 controls) of European descent. A PRS based on 141 CRC-associated genetic variants was modeled as a categorical variable in quartiles...
April 1, 2024: British Journal of Cancer
#34
REVIEW
Tara K Iyer, Alexa N Fiffick, Pelin Batur
Vasomotor symptoms (VMS) are associated with adverse health consequences and can cause significant morbidity for postmenopausal women. Although hormone therapy remains the gold standard of VMS treatment in menopausal women, some women have contraindications to or may choose not to take hormone therapy. This article provides an up-to-date overview of the current evidence-based nonhormone therapies available for managing VMS. Evidence supporting various treatment options is reviewed, including lifestyle interventions, mind-body therapies, procedures, pharmacologic agents, and emerging therapies, such as neurokinin-receptor antagonists...
April 1, 2024: Cleveland Clinic Journal of Medicine
#35
REVIEW
Erin R Uddenberg, Nancy Safwan, Mariam Saadedine, Maria D Hurtado, Stephanie S Faubion, Chrisandra L Shufelt
The risk of cardiovascular disease (CVD) notably increases in the fifth decade of a woman's life, coinciding with the onset of menopause and occurring 10 years later than the similar age-related increase in men. Menopause marks a significant transition in a woman's life and is accompanied by cardiometabolic changes, including a shift in body composition, increased blood pressure, disruptions in lipoproteins, and insulin resistance. There is increasing evidence that the menopause transition is a risk factor for CVD, independent of age-related changes, especially considering that the earlier the onset of menopause, the greater is the CVD risk...
March 22, 2024: Maturitas
#36
JOURNAL ARTICLE
Intira Sriprasert, Stephanie S Kim, Iram Elias Mohammed, Naoko Kono, Roksana Karim, Hooman Allayee, Howard N Hodis, Wendy J Mack, Ronald M Krauss
CONTEXT: The Early vs Late Intervention Trial with Estradiol (ELITE) showed that hormone therapy (HT) reduced atherosclerosis progression among early but not late postmenopausal women (PMW). OBJECTIVE: Determined by time-since-menopause (1) HT effects on lipids and lipoprotein particle subfractions (LPs), (2) associations of estradiol (E2) level with lipids and LPs, (3) associations of lipids and LPs with atherosclerosis progression. DESIGN: Randomized controlled trial stratified by time-since-menopause...
March 28, 2024: Journal of Clinical Endocrinology and Metabolism
#37
JOURNAL ARTICLE
Christian Doll, Elena Hofmann, Robert Preissner, Max Heiland, Ute Seeland, Frank Konietschke, Jalid Sehouli, Saskia Preissner
IMPORTANCE: Sex differences in head and neck cancer (HNC) incidence suggest a potential contribution of sex hormones. OBJECTIVE: To assess the role of exogenous estrogen exposure in the development of HNC in female patients. DESIGN, SETTINGS, AND PARTICIPANTS: This large multicenter cohort study using clinical records from the TriNetX real-world database included 20 years of data (through May 31, 2023) from 87 health care organizations. The TriNetX database was searched for medical records for female patients with and without exogenous estrogen exposure according to their chronological age...
March 28, 2024: JAMA Otolaryngology—Head & Neck Surgery
#38
JOURNAL ARTICLE
Jacqueline Khalil, Hannah Hill, David Kaelber, Gengqing Song
Female sex hormones have been hypothesized to influence the higher prevalence of gastroparesis in females. This study investigated the effects of hormone replacement therapy (HRT) on gastroparesis and its related symptoms, medication use, and diagnostic testing in post-menopausal women. Utilizing the TriNetX platform, we conducted a population-based cohort study involving post-menopausal women aged 50 or older, with and without HRT. One-to-one propensity score matching was performed to adjust for age, race, ethnicity, diabetes, body mass index (BMI), and hemoglobin A1c...
February 29, 2024: Journal of Personalized Medicine
#39
REVIEW
Barbara Owecka, Agata Tomaszewska, Krzysztof Dobrzeniecki, Maciej Owecki
Hair loss is a common clinical condition connected with serious psychological distress and reduced quality of life. Hormones play an essential role in the regulation of the hair growth cycle. This review focuses on the hormonal background of hair loss, including pathophysiology, underlying endocrine disorders, and possible treatment options for alopecia. In particular, the role of androgens, including dihydrotestosterone (DHT), testosterone (T), androstenedione (A4), dehydroepiandrosterone (DHEA), and its sulfate (DHEAS), has been studied in the context of androgenetic alopecia...
February 24, 2024: Biomedicines
#40
JOURNAL ARTICLE
Fionán Donohoe, Yvonne O'Meara, Aidin Roberts, Louise Comerford, Ivaila Valcheva, Una Kearns, Marie Galligan, Michaela J Higgins, Alasdair L Henry, Catherine M Kelly, Janice M Walshe, Martha Hickey, Donal J Brennan
BACKGROUND: Vasomotor symptoms (VMSs) associated with menopause represent a significant challenge for many patients after cancer treatment, particularly if conventional menopausal hormone therapy (MHT) is contraindicated. METHODS: The Menopause after Cancer (MAC) Study (NCT04766229) was a single-arm phase II trial examining the impact of a composite intervention consisting of (1) the use of non-hormonal pharmacotherapy to manage VMS, (2) digital cognitive behavioral therapy for insomnia (dCBT-I) using Sleepio (Big Health), (3) self-management strategies for VMS delivered via the myPatientSpace mobile application and (4) nomination of an additional support person/partner on quality of life (QoL) in women with moderate-to-severe VMS after cancer...
March 12, 2024: Cancers
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
